Core Viewpoint - Peijia Medical-B (09996) experienced a significant increase of over 6%, currently trading at 5.89 HKD, with a transaction volume of 1.9895 million HKD, following the announcement of the acceptance of its TAVR system registration application by the National Medical Products Administration of China [1] Group 1: Company Developments - Peijia Medical announced the receipt of an acceptance notice for the registration application of its TaurusNXT® "non-glutaraldehyde cross-linked" transcatheter aortic valve replacement (TAVR) system [1] - The TaurusNXT® is a third-generation TAVR system developed in-house, utilizing patented non-glutaraldehyde biological tissue cross-linking technology aimed at enhancing the durability and biocompatibility of artificial aortic valves [1] Group 2: Executive Actions - The board of directors has been informed that Dr. Zhang Yi, the executive director, CEO, and chairman of the board, will begin purchasing company shares in the open market starting December 1, 2025, with a total investment not exceeding 15 million HKD [1] - Dr. Zhang's planned share acquisition reflects his recognition of the company's intrinsic value and his strong confidence in the company's development prospects and growth potential [1]
港股异动 | 沛嘉医疗-B(09996)涨超6% Taurus NXT系统注册申请获受理 董事长本月开始增持